Anthony Nolan – Our Stories

Saving the Lives of People with Blood Cancer

  • Home
  • Patient Services & Insight
  • Supporter Stories
  • Science & Policy
  • Donor Stories

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)

Introducing: Anthony Nolan Cell & Gene Therapy Services

Katie GriffeeAugust 18, 2020 by Katie Griffee Leave a Comment

Cell and gene therapies have the potential to be transformative for patients. With the right support, researchers and developers have an opportunity to become leaders in this competitive global market.

The number of allogeneic cell-based therapies in development is greater than ever, but how can organisations ensure they have a sustainable supply of starting material? A material that, unlike traditional pharmaceuticals, cannot simply be manufactured on demand?

At Anthony Nolan, our Cell and Gene Therapy Services were launched to solve this exact need. 

We source and supply donor starting materials to the cell and gene therapy industry, to improve the lives of patients worldwide. Researchers and developers come to us to procure high quality adult and/or cord material, to the specifications and standards that they expect.

Why choose us?

  • Over 45 years’ experience sourcing and transporting cellular material from donor to patient. Today, we replicate this journey to bring cells from the donor to researchers.
  • Our stem cell register gives us access to 850,000 potential donors and our cord blood bank has over 10,000 clinical grade units
  • UK-based, with a global reach through our trusted network of partners. We have established strong partnerships with apheresis centres across the UK
  • Our Cell Therapy Centre has the facilities to manage the processing, characterisation and delivery of materials, and is fully compliant with regulatory requirements
  • We guarantee materials are ethically sourced, ensuring donors are well-informed, and always prioritising their health and safety

We’ve established collaborations with universities, pharma and biotech companies across Europe.

Whether you’re working on an early stage concept, clinical trial or something further afield, we can help you accelerate the development of your pipeline. And with an increasing emphasis on patient-centricity, you can be confident that working in partnership with Anthony Nolan Cell & Gene Therapy Services aligns with your ambition: to improve the lives of patients. 

At Anthony Nolan, we are a partner not just for today but far into the future. Let’s shape the direction of cell and gene therapies together, for the benefit of patients worldwide.

Footnote: All profits are reinvested into Anthony Nolan’s charitable work and so by working with us, you’ll be helping to save and improve the lives of patients with blood cancer and other haematological disorders.

Related

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)

Filed Under: Cell & Gene Therapy

Katie Griffee

Katie Griffee

Katie Griffee is the Business Development manager of Anthony Nolan Cell and Gene Therapy Services. She has a background in Biomedical Sciences and several years’ experience in the pharmaceutical industry. Her aim is to boost awareness of the Cell and Gene Therapy Services and foster new client relationships – to support the research and development of new therapies that have the potential to improve and save patients’ lives.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

What factors should you consider when identifying a cell source provider?

December 17, 2020 by Katie Griffee

HENNY BRAUND: WHAT DOES THE FUTURE HOLD FOR STEM CELL TRANSPLANT RECIPIENTS?

November 24, 2020 by Henny Braund

How can we personalise care in the digital era?

November 3, 2020 by Nusha Haghpanah

‘I was 6 months pregnant when I was told I needed a bone marrow transplant’ – Sophie’s story

November 3, 2020 by Clare McCrudden

Launching our report: Stem cell transplants and COVID-19: What have we learnt from patients during the pandemic?

October 29, 2020 by Charlotte Wickens

Post categories

  • Cell & Gene Therapy
  • Cord blood
  • Donor Stories
  • Patient Services & Insight
  • Science & Policy
  • Scientific Research
  • Supporter Stories
  • Uncategorized

Enter your email address to subscribe to this blog and get new posts via email

Links

  • Home
  • Patient Services & Insight
  • Supporter Stories
  • Science & Policy
  • Donor Stories

Follow Us

Terms & Conditions

Privacy Policy and Cookies

Anthony Nolan is a registered charity no 803716/SC038827 and a registered company no 2379280

© 2021 Anthony Nolan · anthonynolan.org